Lannett has underlined plans to file both of its proposed insulin biosimilars in the US in the first half of calendar 2023, following a planned US Food and Drug Administration submission for its proposed generic Flovent Diskus (fluticasone) dry powder inhaler early in the new year, as the company looks finally to reverse its fortunes with a slate of big-ticket launches in the coming years.
The US-based company is now “over 90% complete with subject dosing in our healthy volunteer glargine study,” which has so far seen no serious adverse events
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?